Tasly Pharmaceutical Group Co., Ltd. Signs Cooperation Agreement to Promote the Development of the Dual-Target CAR-T Project

China Visitor Network Data: Tasly Pharmaceutical Group Co., Ltd. announced on March 20, 2026, that it has signed a “Cooperation Agreement” with Beijing Neurosurgical Institute and its affiliated Beijing Rencheng Neuro-Oncology Biotechnology Engineering Research Center Co., Ltd., aiming to jointly promote the research, development, and commercialization of an autologous CAR-T product targeting CD44 and/or CD133. The product received clinical approval for recurrent glioblastoma in April 2025 and has entered Phase I clinical trials.

According to the agreement, Tasly will serve as the marketing authorization holder for the product, leading subsequent research and development, registration applications, and commercialization efforts, and will have exclusive rights to the product’s production and commercialization. Beijing Neurosurgical Institute, as the core technology holder, will continue to provide R&D support and will receive tiered sales commissions based on net sales after the product’s launch. The affiliated Beijing Rencheng Biotech will act as a co-developer, providing technical and financial support during specific R&D phases, sharing R&D risks with Tasly.

The total estimated R&D expenditure for this project is 240 million RMB. Tasly plans to invest approximately 160 million RMB (including expenses during the IND phase), while Beijing Rencheng Biotech is expected to contribute about 80 million RMB after dose exploration is completed. Both parties will share the rights to the sales profits generated from the product’s indication for recurrent glioma based on their proportion of audited actual R&D investments.

This related-party transaction has been approved by the 18th meeting of the Ninth Board of Directors and the first special meeting of independent directors in 2026. Independent directors believe that this cooperation will help integrate external resources, accelerate core product development, align with the company’s strategic development, and that the transaction pricing and profit-sharing mechanisms are fair, without harming the interests of the company or minority shareholders. The company states that this move is a key step in deepening its strategic layout in the field of cellular immunotherapy.